Home › Trial NCT01106352
A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)
- Trial IDNCT01106352
- StatusCompleted
- PhasePhase 1/2
- Study typeInterventional
- SponsorBayer
- Enrollment70
- Start date2010-07
- ConditionsBone Metastases · Castration-Resistant Prostate Cancer
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.